Detection of remaining Plasmodium DNA and gametocytes during follow up after curative malaria treatment among returned travellers in Norway

Table 2 PCR results associated with microscopy findings and clinical characteristics

Patient	Species	No. days since treatment	Microscopy (parasite%)	PCR	Fever duration before treatment (days)	Treatment	Origin/years out of endemic area	Comorbidity
No. 1	P.f + P.m	0	Pos (2)	Pos	35	AL	SSA/1	HIV
No. 1	P.f + P.m	1	Pos (1)	Pos^b,c
No. 2	P.f	0	Pos (4)	Pos	2	A, AL	SSA/8	HIV
No. 2	P.f	1	Pos (4)	Pos^b,c
No. 3	P.f	0	Pos (12)		3	A, AP	Norway
		1	Neg	Pos
		2	Neg	Pos
		11	Neg	Pos^b
No. 4	P.f	0	Pos (< 1)^a		38	AP	SSA/10
No. 4	P.f	31	Neg	Neg
No. 5	P.f	0	Pos (< 1)		7	AL	SSA/46
No. 5	P.f	32	Neg	Pos
No. 6	P.f	0	Pos (2)	Pos	9	Q, A, AL	SSA/21
		1	Pos (< 0.5)	Pos^b,c
		37	Neg	Pos
No. 7	P.f	0	Pos (10)	Pos	21	A, AL	SSA/10	HIV
		4	Neg	Pos
		11	Neg	Pos
		39	Neg	Neg
No. 8	P.f	0	Pos (30)	Pos	3	A,	Norway
		1	Pos (6)	Pos^b,c		Erythrocyte
		45	Neg	Pos		apheresis, AL
No. 9	P.f	0	Pos (6)^a		13	A, AP, AL	SSA/17	Sickle cell disease
No. 9	P.f	49	Neg	Pos				Sickle cell disease
No.10	P.v	0	Pos (0.5)		10	AP, P	SEA/30
No.10	P.v	2	Pos^a	Pos^b,c
No. 11	P.v	0	Pos (0.5)^a		Not known	AP, P	SSA
No. 11	P.v	6	Neg	Pos	Not known
No. 12	P.v	0	Pos	Pos	2	A, AP, P	Norway
No. 12	P.v	23	Neg	Neg
No. 13	P.v	0	Pos		6	C, P	Norway
No. 13	P.v	54	Neg	Neg

AL artemether-lumefantrine, A artesunate IV (intravenous), PA atovaquone-proguanil, Q quinine IV, C chloroquine, P primaquine, HIV human immunodeficiency virus, SSA sub-Saharan Africa, SEA Southeast Asia
^aGametocytes seen by microscopy
^bDetection of 18S mRNA transcripts (Produced by all parasite stages)
^cDetection of gametocyte-specific mRNA

ISSN: 1475-2875